Sign Up Today and Learn More About Memo Therapeutics Stock
Invest in or calculate the value of your shares in Memo Therapeutics or other pre-IPO companies through EquityZen's platform.
Memo Therapeutics Stock (METU)
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.
About Memo Therapeutics Stock
Founded
2012
Industries
Software, Artificial Intelligence, Data and Analytics
Memo Therapeutics Press Mentions
Stay in the know about the latest news on Memo Therapeutics
Frits van Alphen gets Memo CDO job
thepharmaletter • Nov 06, 2024
Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer
globenewswire • Nov 04, 2024
Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer
morningstar • Nov 04, 2024
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients
globenewswire • Nov 01, 2024
Memo Therapeutics boosts Series C Financing to CHF 45 million, advancing antibody development against BKV infection
venturelab • Sep 20, 2024
Memo Therapeutics Management
Leadership team at Memo Therapeutics
Member of the board
Michael Sidler
Board of Director
Christian Schneider
Join now and verify your accreditation status to gain access to:
- Memo Therapeutics current valuation
- Memo Therapeutics stock price
- Available deals in Memo Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Memo Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Memo Therapeutics through EquityZen funds. These investments are made available by existing Memo Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Memo Therapeutics stock?
Shareholders can sell their Memo Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
